WO1997039134A1 - Particule du type virus - Google Patents

Particule du type virus Download PDF

Info

Publication number
WO1997039134A1
WO1997039134A1 PCT/GB1997/001065 GB9701065W WO9739134A1 WO 1997039134 A1 WO1997039134 A1 WO 1997039134A1 GB 9701065 W GB9701065 W GB 9701065W WO 9739134 A1 WO9739134 A1 WO 9739134A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
nucleic acid
virus
cell
particle
Prior art date
Application number
PCT/GB1997/001065
Other languages
English (en)
Inventor
Thomas Michael Aubrey Wilson
Sean Nicholas Chapman
Original Assignee
Scottish Crop Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scottish Crop Research Institute filed Critical Scottish Crop Research Institute
Priority to AU25725/97A priority Critical patent/AU2572597A/en
Priority to EP97917344A priority patent/EP0886680A1/fr
Publication of WO1997039134A1 publication Critical patent/WO1997039134A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • Virus-like particle This invention relates to a virus-like particle, especially to a pseudovirus particle, and to a method for the production of a chimaeric protein using such virus-like particles.
  • the protein can be a capsid protein which can self assemble in vivo with the nucleic acid (which may be chimaeric) to form the virus-like particles.
  • Pseudovirus particles are virus-like particles comprising viral coat protein subunits and a portion of the wild-type viral nucleic acid. Pseudoviruses may also include foreign nucleic acid.
  • the coat protein can be wild-type, modified or chimaeric.
  • a pseudovirus may lack at least a portion of the wild-type viral nucleic acid (or may possess a non-functional analogue of the wild-type nucleic acid) and this commonly renders the pseudovirus incapable of some function which is characteristic of the wild-type virus, such as replication.
  • other genes may be missing or disabled, and the pseudovirus may be, for example, replication competent but incapable of cell-cell movement.
  • the missing or dysfunctional gene(s) can be provided on the genome of a host cell or on a plasmid etc present in the host cell, thereby restoring the function of the wild-type virus to the pseudovirus when in the host cell.
  • the physical properties of the pseudovirus particle such as shape, symmetry, nucleic acid.protein ratio are usually similar to or identical with the wild-type virus from which the pseudovirus is derived, although particle length and width can be influenced by nucleic acid length and coat protein composition respectively.
  • a virus-like particle comprising nucleic acid and protein, the protein having a first (viral) portion and a second (non-viral) portion.
  • virus-like particle refers to self-assembling particles which have a similar physical appearance to virus particles and includes pseudoviruses. Virus-like particles may lack or possess dysfunctional copies of certain genes of the wild-type virus, and this may result in the virus-like- particle being incapable of some function which is characteristic of the wild-type virus, such as replication and/or cell-cell movement.
  • the nucleic acid can be DNA or RNA, according to the genome of the virus from which the virus-like particle is derived.
  • the nucleic acid may comprise an origin- of-assembly sequence (OAS) by which we mean a nucleic acid sequence which permits initiation of assembly of the protein and nucleic acid into virus-like particles.
  • OFS origin- of-assembly sequence
  • a method of producing a protein having a first (viral) portion and a second (non-viral) portion comprising expressing the protein in a cell, providing a nucleic acid sequence capable of assembly with the protein into a virus-like particle (VLP), and permitting in vivo assembly of the protein and nucleic acid into VLPs.
  • VLP virus-like particle
  • the virus-like particles can be purified from the cell by standard techniques such as centrifugation etc, and the chimaeric protein can optionally be cleaved to release the second portion from the first portion, or separated entirely from the nucleic acid. If the chimaeric protein is left attached to the virus-like particle, the whole virus-like particle can also be used for presentation of peptide epitopes for vaccination of animals, the production of therapeutic or industrial proteins and polypeptides and/or the delivery of therapeutic nucleic acid molecules (optionally targeted delivery), such as ss or ds DNA or RNA, including antisense molecules.
  • the nucleic acid can advantageously be provided from a plasmid in the cell, possibly by transcription of such a plasmid-.
  • the protein may be encoded by the same or another plasmid in the cell.
  • one or both of the nucleic acid and protein can be coded from the genome of the cell.
  • the cell is preferably a bacterium such as E. coli although other forms of bacteria and other cells may be useful, such as mammalian cells, plant cells, yeast cells and insect cells.
  • the cell may be a natural host cell for the virus from which the virus-like particle is derived, but this is not necessary*
  • a cell for the assembly of the virus-like particle in vivo enables facile cell handling techniques to be employed to facilitate purification of virus-like particles and purification of protein.
  • a different (eg bacterial) cell may be employed.
  • the nucleic acid is preferably chosen in accordance with its ability to assemble with the viral protein.
  • the virus-like particle may be derived from tobacco mosaic virus (TMV) .
  • the first portion of the protein is preferably derived from TMV coat protein (CP), and the nucleic acid has at least an OAS of eg 75 or more nucleotides derived from TMV RNA.
  • the sequence of the remainder of the nucleic acid is not important, and it can be chosen to code for the chimaeric protein or may be of some other eg unrelated or therapeutic sequence.
  • nucleic acid in the virus-like particle means that the particle is of helical symmetry and more stable than simple aggregations of protein (eg planar, stacked or helical arrays), which are normally created at low pH in vitro from purified TMV coat protein, and can dissociate outside a narrow pH range.
  • the length of the particle can be selected by specifying a particular length of nucleic acid. This results in a more uniform range of particle sizes, which has advantages in purification procedures such as centrifugation, and in defining and regulating the quality control for products for medical use.
  • a further advantage with the use of nucleic acid in the assembly of virus-like particles is that the resultant particle can have a regular multivalent and true helical structure which can be more immunogenic than an aggregation of protein or free subunits of protein.
  • the greater stability of the particle can also provide longer access to the immune system in certain embodiments.
  • the second portion of the chimaeric protein is preferably disposed on the outer surface of the virus- like particle.
  • the second portion can be disposed on the amino or carboxy terminus, or inserted in eg an internal loop disposed on the outer surface of the CP. This can result in improved assembly as compared with the assembly of particles having a second portion on another location of the CP, and can enhance immune recognition of the second portion on the particle surface, which is useful for embodiments where the CP is an immunogen such as a vaccine. In certain cases it may be possible to provide large second portion proteins.
  • virus which is flexuous ie which can bend easily
  • chimaeric proteins with large second portions may be able to assemble more easily into virus particles which are flexuous than those which are rigid.
  • PVX is preferred since it forms a flexuous particle.
  • a linker peptide can be incorporated between the first and second portions and may have the function of spacing the two portions from one another, reducing steric restrictions.
  • the linker peptide may contain a cleavage site.
  • cleavage site refers to a short sequence of amino acids which is recognisable and subsequently cleavable by eg a proteolytic enzyme or by chemical means. Suitable proteolytic enzymes include trypsin, pepsin, elastase, factor Xa etc. Alternatively the cleavage site may be vulnerable to cleavage by other means, for example by addition of chemicals such as cyanogen bromide (CNBr) or acids.
  • CNBr cyanogen bromide
  • cleavage site may also include sequences that self-leave such as the FMDV (Foot and Mouth Disease Virus) 2A protease.
  • the cleavage site may be an integral part of either the first or second portion. Hence either/or both of the portions may include an integral cleavage site.
  • the second portion protein may be a short oligopeptide (10-40 amino acids) or a relatively large polypeptide eg over lOkDa. Proteins of 25-30 kDa may also be suitable for production by the method of the invention.
  • the first (viral) portion of the chimaeric protein may be any protein, polypeptide or parts thereof, derived from a viral source including any genetically modified versions thereof (such as deletions, insertions, amino acid replacements and the like) .
  • the first portion will be derived from a viral coat protein (or a genetically modified version thereof). Mention may be made of the coat protein of Potato Virus X as being suitable for this purpose.
  • the first portion has the ability to assemble into virus-like particles by first- portion/first portion association.
  • a chimaeric protein molecule can assemble with other chimaeric protein molecules or with wild-type coat protein into a chimaeric virion.
  • the particle is derived from a tobamovirus such as tobacco mild green mosaic virus TMGMV), tobacco mosaic virus (TMV), or from a potexvirus such as PVX, and in such an embodiment, the second portion is preferably disposed at or adjacent the N-terminus of the coat protein.
  • TMGMV tobacco mild green mosaic virus
  • TMV tobacco mosaic virus
  • PVX potexvirus
  • the N-terminus of the coat protein is believed to form a domain on the outside of the virion.
  • the second portion of the chimaeric protein may be any protein, polypeptide or parts thereof, including any genetically modified versions thereof (such as deletions, insertions, amino acid replacements and the like) derived from a source other than the virus from which the first portion is derived.
  • the second portion or the protein derived therefrom is a biologically active or otherwise useful molecule.
  • the second portion or the protein derived therefrom may also be a diagnostic reagent, an antibiotic or a therapeutic or pharmaceutically active agent.
  • the second portion protein may be a food supplement.
  • the first portion it is not necessary for the first portion to comprise a whole virus coat protein, but this remains an option. Some no-essential amino acids could be removed during construction of the CP gene.
  • the virus particle may be formed by the assembly of chimaeric proteins only or by the mixed assembly of chimaeric proteins together with some unmodified or less modified forms of the naturally occurring wild- type coat protein which forms the basis of the first portion.
  • a mixed virus particle of the latter type there must be present polynucleotide(s) encoding the chimaeric protein and the naturally occurring coat protein.
  • the appropriate protein-coding sequence(s) may be arranged in tandem on the same molecule, or could be generated by differential RNA splicing Alternatively, the different proteins could be translated from the same nucleotide sequence and modified later, eg by in vivo processing such as self cleavage.
  • a chimeric CP gene encoding eg GFP-2A-CP fusion protein, which is expressed from a single gene (eg on a plasmid, from the genome of the cell, or from the RNA of the VLP) and which self cleaves a variable number of the translated proteins into separate GFP and CP, a proportion of the translated proteins remaining uncleaved as GFP-2A-CP.
  • a heterologous mixture of CPs can be assembled into a VLP, with eg every 10th CP bearing a second portion, and the remaining CPs being cleaved, native (or substantially native) CPs.
  • Suitable co-translational cleavage sequences can be chosen for particular cell types. The efficiency of the co-translational cleavage can be modified to produce the required proportion of cleaved/whole CPs in the assembled VLP.
  • PVX has a pitch of 3.4nm and is to be preferred over viruses with a lower pitch.
  • Virus particles with higher pitches may be able to accommodate larger protein insertions on their surfaces since their coat proteins assemble with more space between them than coat proteins of viruses with lower pitches.
  • the method can be used for expression of metabolic enzymes for pathway engineering, nutritional supplements (eg hi-met proteins), anti-potato cyst nematode lectins, gut protease inhibitors, anti- botrytis agents, PGIPs, anti-insect Bacillus thuringiensis toxin and herbicide resistance agents, industrial enzymes, pharmaceuticals, therapeutic proteins and nucleic acids, and as bioreactors.
  • Fig 1 is a schematic representation of the plasmid pA27;
  • Fig 2 is an SDS PAGE analysis of proteins from purified TMV and pseudovirions . Samples were electrophoresed on an SDS/PAGE gel and silver stained. Lane 1, purified TMV. Lane 2, VLPs purified from E. coli BL21(DE3) cells transformed with plasmids pA27 and pLysl02. The positions of coelectrophoresed marker proteins and their molecular weights in kDa are shown to the left; Fig 3 is an electron microscope image of VLPs . VLPs purified from E.
  • coli BL21(DE3) cells transformed with plasmids pA27 and pLysl02 were negatively stained with 2% sodium phosphotungstate pH 5.0 and viewed in the electron microscope.
  • Fig 4 shows sequence information for LITMUS 39 plasmids used in Example 2;
  • Fig 5 shows a schematic representation of cDNA constructs used in Example 2;
  • Fig 6 shows immunoblot analysis of extracts of leaves probed with anti-CP antiserum;
  • Fig 7 shows immunoblot analysis of virus prepared from plants infected with a VLP.
  • Example 1 A sequence encoding two glycine residues and an eight amino acid antigenic epitope (EQPTTRAQ) from VP1 of poliovirus type 3 [1] was fused to the 3' end of a synthetic gene coding for the tobacco mosaic virus (TMV) coat protein by PCR amplification with mutagenic primers.
  • TMV tobacco mosaic virus
  • the plasmid pTMVCP [1] was used as a template for amplification with primers P1311 (5' AAG-AAT-TCA- TAT-GTC-TTA-TTC-GAT-TAC-C 3') and P1312 (5' AAG-GAT- CCT-CAC-TGA-GCA-CGA-GTA-GTC-GGC-TGT-TCA-CCA-CCA-GTT- GCC-GGG-CCC-GAG 3').
  • the amplification product was treated with T4 DNA poly erase to make it blunt-ended and ligated into EcoRV digested pKR [2].
  • the ligation products were transformed into E. coli strain JM101. Transformants were screened for the desired plasmid, pAll, containing the gene encoding the modified TMV coat protein.
  • a fragment encompassing the modified gene was cloned into an expression vector, under the transcriptional control of T7 promoter and T ⁇ terminator sequences.
  • the plasmid pAll was digested with Ndel and fiamHI and the 510 base pair fragment released was cloned between the same sites of pET3a [3].
  • the nucleotide sequence of the resulting plasmid, pA27 ( Figure 1), in the region encoding the eight amino acid epitope and the linker of two glycine residues, was confirmed by nucleotide sequence determination.
  • sequence encoding TMV coat protein and ten amino acid peptide fused to the carboxy-terminus are indicated by boxes marked TMV CP and PEP respectively. Restriction endonuclease sites used for the introduction of the modified TMV coat protein gene into the plasmid pET3a are indicated above.
  • the T7 promoter and T ⁇ terminator sequences from the plasmid pET3a are indicated by a double thickness arrow and line respectively.
  • the nucleotide sequence of the 3' end of the modified TMV coat protein gene and the amino acids encoded by this sequence are shown below.
  • the nucleotide sequence encoding the additional ten amino acids and the amino acids themselves are shown in bold.
  • the plasmid pA27 was transformed into E. coli BL21(DE3) cells that had previously been transformed with the plasmid pLysl02 [4].
  • the plasmid pLysl02 produces a chimaeric RNA transcript encoding chloramphenicol acetyl transferase and containing the TMV origin-of-assembly sequence, which when co-synthesized with TMV coat protein in E. coli directs the assembly of pseudovirus particles of 70nm length (modal) and 18nm diameter.
  • TMV coat protein-related protein with a slightly lower mobility than unmodified TMV coat protein was detected by Coomassie blue staining and immunoblotting of SDS/PAGE gels as described by Hwang et al . [4].
  • VLPs containing the modified TMV coat protein were purified using a protocol based on that described by Hwang et al . [4].
  • Colonies of BL21(DE3) co-transformed with pA27 and pLysl02 were used to inoculate 5 ml of M9ZB medium supplemented with 100 ⁇ g/ml a picillin and 35 ⁇ q/ml chloramphenicol. Cultures were grown overnight at 37°C. The bacteria were pelleted from the overnight cultures and used to inoculate 500 ml of M9ZB medium supplemented with ampicillin and chloramphenicol. The large-scale cultures were grown at 37°C until mid-log phase (A « 0 o s 0.7).
  • Bacterial debris was removed by centrifugation (20800 x g, 4°C, 30 min) .
  • the resulting supernatants were extracted with 10 ml of chloroform and the two phases separated by centrifugation (9200 x g, 4°C, 10 min).
  • 3.7 ml of 5M NaCl and 2.63 ml of 40% polyethylene glycol (average molecular weight 6000) were added to 20 ml of the aqueous phase.
  • the solutions were mixed and incubated on ice for 60 min.
  • Precipitated material was collected by centrifugation (20800 x g, 4°C, 15 min).
  • the pelleted material was resuspended in 1 ml of TE.
  • Insoluble material was removed by centrifugation (16000 x g, 4°C, 5 min) .
  • the supernatant was centrifuged (160000 x g, 4°C, 120 min) on a sucrose gradient (10- 40% w/v in TE) .
  • Fractions were collected from the gradients and those containing helical TMV-like particles, assessed by double-antibody sandwich ELISA with a mouse monoclonal antibody specific for an epitope in the TMV coat protein helix as described by Hwang et al. [4], were pooled for further purification.
  • VLPs were collected by centrifugation (235,000 x g, 15°C, 150 min) .
  • Pelleted pseudovirions were resuspended in 0.5 ml of TE.
  • Insoluble material was removed by centrifugation (840 x g, 4°C, 5 min).
  • the supernatant was centrifuged (189,000 x g, 15°C, 120 min) on a CsCl gradient (10-40% (wt/wt) in TE). Bands containing pseudovirus were collected from the gradients and dialyzed against 50 mM sodium phosphate pH 7.0.
  • the yield of VLPs was estimated by measuring the absorption at 260 run.
  • the final yield of pseudovirus was 5.8 mg from 500 ml of culture.
  • the purity of the pseudovirus preps was assessed by silver staining of samples electrophoresed on SDS/PAGE gels ( Figure 2).
  • Figure 2 On SDS/PAGE gels the unmodified TMV coat protein produced by pET302 and the modified coat protein produced by pA27 migrate relative to protein standards (Bio-Rad) with apparent molecular weights of 20.9 kDa and 22.6 kDa respectively.
  • the predicted molecular weights for these two proteins are 17.7 kDa and 18.6 kDa respectively.
  • pseudovirus preparations The integrity of the pseudovirus preparations was assessed by negative staining of pseudovirus samples with 2% sodium phosphotungstate and observation of the stained samples in the electron microscope ( Figure 3). Pseudovirus preparations were diluted to 1 mg / ml in 50 mM sodium phosphate pH 7.0 for immunization of mice.
  • Example 2 A plasmid containing the tobacco mild green mosaic virus (TMGMV) coat protein (CP) gene and 3' untranslated region (UTR) was produced to facilitate the production of green fluorescent protein (GFP), foot-and-mouth disease virus 2A, TMGMV CP gene fusions.
  • GFP green fluorescent protein
  • Bp Bp
  • TMGMV-CP-Apa 5' CAA-TGG-GCC-CTA-TAC-AAT-CAA- CTC-T 3'
  • M13-Reverse 5' AGC-GGA-TAA-CAA-TTT-CAC- ACA-GGA 3'.
  • the primer TMGMV-CP-Apa was designed to mutagenize the sequence coding for the initiating ethionine and first proline codon of the TMGMV CP to an Apal restriction enzyme site. This results in the conversion of the methionine codon to a glycine codon, but maintains the proline codon.
  • the 837bp fragment released by digestion of the PCR amplification product with the restriction endonucleases Apal and Kpnl was cloned into the 3322bp fragment released by digestion of pSLll ⁇ O (Pharmacia) digested with the same restriction endonucleases and treated with calf intestinal alkaline phosphatase.
  • the resulting plasmid was named pSL.TMGMV-CP-UTR.
  • CFP-2A-TMGMV CP gene fusions were produced by cloning DNA fragments containing GFP-2A fusions into pSL.TMGMV- CP-UTR adjacent to the codon for the first proline in the TMGMV CP gene.
  • a selection of LITMUS 39 (New England Biolabs) based plasmids containing GFP-2A- potato virus X CP gene fusions were used as sources for the GFP-2A gene fusion.
  • plasmids contain a variety of sequences coding for different 2A amino acid sequences between the carboxy-terminal lysine codon of GFP and the first proline codon of the PVX CP. Fragments of between 900 and 1050bp were PCR amplified from the plasmids pLit, GFP-2A 16H -CP, pLit.GFP-2A 16K -CP, pLit.GFP-2A 23H -CP and pLit.GFP-2A MK -CP using the primers GFP-5'-Sal (5' TCA- ATC-GTC-GAC-ATG-AGT-AAA-GGA-GAA-GAA 3') and N3#4 (5' TGT-ACT-AAA-GAA-ATC-CCC-ATC-C 3').
  • the primer GFP-5'- Sal introduces a Sail restriction enzyme site upstream of the initiating methionine codon of the GFP gene. Fragments containing the GFP gene fused to the different 2A sequences were released by digestion of the PCR amplification products with Sail and Apal and ligated into the large fragment released by digestion of pSL.TMGMV-CP-UTR with the same restriction enzymes and treated with calf intestinal phosphatase.
  • the resulting plasmids were digested with Sail and BstEII and the released fragments containing the GFP-2A-TMGMV CP gene fusion and TMGMV UTR were introduced into the plasmid 30B digested with Xhol and BstEII to regenerate full-length TMV based clones.
  • the final clones comprise wild-type TMV strain Ul sequence up to position 5757 in the CP gene, with the exception of a mutagenized CP initiating methionine codon, followed by a short polylinker sequence, the GFP-2A-TMGMV CP gene fusions and the TMGMV 3' UTR.
  • transcripts derived from all the plasmids were infectious when inoculated onto Nicotiana benthamiana plants; virus derived from transcript- infected plants is referred to subsequently by the name of the progenitor plasmid without the "p" prefix.
  • virus derived from transcript- infected plants is referred to subsequently by the name of the progenitor plasmid without the "p" prefix.
  • all the viruses caused the development of fluorescent regions which were first detectable by eye under UV illumination between three and four days post inoculation. Subsequent long distance movement of the virus led to the appearance of green fluorescence in systemically infected leaves.
  • Protein was prepared from mock-inoculated control plants (lane 1) or from plants inoculated with in vitro transcripts synthesized from plasmid DNAs (p30B.GFP, lane 2; p30B.GFP-2A 23H -CP, lane 3; p30B.GFP2A 16H -CP, lane 4; p30B.GFP-2A 16K -CP, lane 5; p30B.GFP-2A 58K -CP, Lane 6). Lane 7 contains 125ng of TMGMV CP.
  • the predicted Mr values of TMGMV CP, GFP and GFP-2A-CPS are 17.5 kDa, 26.9 kDa and between 46 and 52 kDa, respectively.
  • the Mr values of standards (X10. 3 ) are shown on the left.
  • Coating antiserum 30B GFP 30B .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur des particules chimériques pseudovirales et une méthode d'obtention d'une protéine étrangère faisant appel à ces particules. Les particules pseudovirales consistent en une protéine (par exemple une protéine de coque) présentant une partie virale et une partie non virale, et en un acide nucléique (facultativement chimérique) stabilisant l'agrégation de la protéine et créant un ribonucléocapside en hélice dont la structure et la symétrie sont proches de celles du virus d'origine.
PCT/GB1997/001065 1996-04-17 1997-04-17 Particule du type virus WO1997039134A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU25725/97A AU2572597A (en) 1996-04-17 1997-04-17 Virus-like particle
EP97917344A EP0886680A1 (fr) 1996-04-17 1997-04-17 Particule du type virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9607899.3 1996-04-17
GBGB9607899.3A GB9607899D0 (en) 1996-04-17 1996-04-17 Virus-like particle

Publications (1)

Publication Number Publication Date
WO1997039134A1 true WO1997039134A1 (fr) 1997-10-23

Family

ID=10792174

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/001065 WO1997039134A1 (fr) 1996-04-17 1997-04-17 Particule du type virus

Country Status (4)

Country Link
EP (1) EP0886680A1 (fr)
AU (1) AU2572597A (fr)
GB (1) GB9607899D0 (fr)
WO (1) WO1997039134A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000224A2 (fr) * 1998-06-29 2000-01-06 November Ag Novus Medicatus Bertling Gesellschaft Für Molekulare Medizin Procede pour amener une substance moleculaire dans des zones predeterminees de cellules eucaryotes
WO2000011175A1 (fr) * 1998-08-18 2000-03-02 Syngenta Limited Methode genetique d'expression de polyproteines dans des plantes
WO2001066778A2 (fr) * 2000-03-08 2001-09-13 Large Scale Biology Corporation Production de polypeptides etrangers dans des plantes sous forme d'hybrides de proteine de coque virales
WO2004004761A2 (fr) 2002-07-05 2004-01-15 Denis Leclerc Particule virale d'adjuvant
EP1381388A1 (fr) * 2001-03-29 2004-01-21 Large Scale Biology Corporation Production de peptides dans les plantes en tant que fusions de proteines de coque virales n-terminales
US6890748B2 (en) 2000-07-26 2005-05-10 Large Scale Biology Corporation Production of lysosomal enzymes in plants by transient expression
WO2008058369A1 (fr) 2006-11-15 2008-05-22 Folia Biotech Inc. Systèmes d'antigène conjugué par affinité immunogène fondés sur le virus de la mosaïque de la papaye et utilisation de ceux-ci
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010624A1 (fr) * 1993-10-14 1995-04-20 Boehringer Ingelheim International Gmbh Particules a activite endosomolytique
WO1996005292A1 (fr) * 1994-08-15 1996-02-22 Connaught Laboratories Limited Particules retroviriformes non infectieuses a marquage antigenique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010624A1 (fr) * 1993-10-14 1995-04-20 Boehringer Ingelheim International Gmbh Particules a activite endosomolytique
WO1996005292A1 (fr) * 1994-08-15 1996-02-22 Connaught Laboratories Limited Particules retroviriformes non infectieuses a marquage antigenique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M.N. JAGADISH ET AL.: "High level production of hybrid Potyvirus-like particles carrying repetitive copies of foreign antigens in Escherichia coli", BIO/TECHNOLOGY., vol. 11, no. 10, October 1993 (1993-10-01), NEW YORK US, pages 1166 - 1170, XP002040652 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000224A2 (fr) * 1998-06-29 2000-01-06 November Ag Novus Medicatus Bertling Gesellschaft Für Molekulare Medizin Procede pour amener une substance moleculaire dans des zones predeterminees de cellules eucaryotes
WO2000000224A3 (fr) * 1998-06-29 2000-04-13 November Ag Molekulare Medizin Procede pour amener une substance moleculaire dans des zones predeterminees de cellules eucaryotes
WO2000011175A1 (fr) * 1998-08-18 2000-03-02 Syngenta Limited Methode genetique d'expression de polyproteines dans des plantes
US7413889B2 (en) 2000-03-08 2008-08-19 Kentucky Bioprocessing, Llc Production of a parvovirus vaccine in plants as viral coat protein fusions
US7270825B2 (en) 2000-03-08 2007-09-18 Large Scale Biology Corporation Production of a parvovirus vaccine in plants as viral coat protein fusions
WO2001066778A2 (fr) * 2000-03-08 2001-09-13 Large Scale Biology Corporation Production de polypeptides etrangers dans des plantes sous forme d'hybrides de proteine de coque virales
WO2001066778A3 (fr) * 2000-03-08 2002-05-10 Large Scale Biology Corp Production de polypeptides etrangers dans des plantes sous forme d'hybrides de proteine de coque virales
US6730306B1 (en) 2000-03-08 2004-05-04 Large Scale Biology Corporation Parvovirus vaccine as viral coat protein fusions
US6890748B2 (en) 2000-07-26 2005-05-10 Large Scale Biology Corporation Production of lysosomal enzymes in plants by transient expression
EP1381388A4 (fr) * 2001-03-29 2005-04-13 Large Scale Biology Corp Production de peptides dans les plantes en tant que fusions de proteines de coque virales n-terminales
EP1381388A1 (fr) * 2001-03-29 2004-01-21 Large Scale Biology Corporation Production de peptides dans les plantes en tant que fusions de proteines de coque virales n-terminales
WO2004004761A2 (fr) 2002-07-05 2004-01-15 Denis Leclerc Particule virale d'adjuvant
US7641896B2 (en) 2002-07-05 2010-01-05 Folia Biotech Inc. Adjuvant viral particle
EP2272525A2 (fr) 2002-07-05 2011-01-12 Folia Biotech Inc. Particule virale adjuvante
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
US8282940B2 (en) 2002-07-05 2012-10-09 Folia Biotech Inc. Adjuvant viral particle
US9339535B2 (en) 2002-07-05 2016-05-17 Folia Biotech, Inc. Vaccines and immunopotentiating compositions and methods for making and using them
WO2008058369A1 (fr) 2006-11-15 2008-05-22 Folia Biotech Inc. Systèmes d'antigène conjugué par affinité immunogène fondés sur le virus de la mosaïque de la papaye et utilisation de ceux-ci

Also Published As

Publication number Publication date
GB9607899D0 (en) 1996-06-19
AU2572597A (en) 1997-11-07
EP0886680A1 (fr) 1998-12-30

Similar Documents

Publication Publication Date Title
Zeltins Construction and characterization of virus-like particles: a review
Smith et al. Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications
CA1340776C (fr) Proteines antigeniques multispecifiques
JPH10508468A (ja) ウイルスコートタンパク質融合体としての植物中でのペプチドの発現
US5100784A (en) Process for the preparation of mature human serum albumin
US6232099B1 (en) Method of producing a chimeric protein
HU223078B1 (hu) Heterológ peptidek kifejezésére alkalmas, vektorként használható módosított növényi vírusok
JPH08503602A (ja) 弱毒化細菌における組換え融合タンパク質の発現
AU2001245509B2 (en) Production of foreign polypeptides in plants as viral coat protein fusions
JPH09500540A (ja) ワクチン組成物
JPH0690769A (ja) バキュロウイルス発現系
CN113121704B (zh) 基于纳米颗粒的冠状病毒疫苗
KR100338894B1 (ko) 백신조성물
AU2001245509A1 (en) Production of foreign polypeptides in plants as viral coat protein fusions
WO1997039134A1 (fr) Particule du type virus
WO2002004007A9 (fr) Formes (fixes) stables de proteines virales capsidiales et de proteines virales capsidiales hybrides, de preference les proteines l1 du papillomavirus, et leurs utilisations
Legendre et al. Production in Saccharomyces cerevisiae of MS2 virus-like particles packaging functional heterologous mRNAs
Martí et al. Production of potyvirus-derived nanoparticles decorated with a nanobody in biofactory plants
CN107119058B (zh) 一种ms2衣壳蛋白融合表达方法及其应用
EP0527767A1 (fr) Systeme d'expression auto-polymerisante a base de proteines enveloppantes de potyvirus modifiees
WO2023125739A1 (fr) Particule de type viral, son procédé de préparation et son utilisation
Hwang et al. Assembly of tobacco mosaic virus and TMV-like pseudovirus particles in Escherichia coli
WO1986003779A1 (fr) Vecteur de secretion de polypeptides, micro-organismes transformes par ledit vecteur, et procede de preparation de polypeptides avec lesdits micro-organismes
Wang et al. Preparation of a peptide vaccine against GnRH by a bioprocess system based on asparaginase
JP3936661B2 (ja) タンパク質を検出または精製するためのウィルスの使用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1997917344

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1997917344

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97536879

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1997917344

Country of ref document: EP